English: o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis; o eplerenone due to an increased risk of hyperkalemia and hypotension; o substances that may have their plasma concentrations increased and have QT prolonging potential : methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine; o dabigatran due to an increased bleeding risk; o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and respiratory depression; o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse reactionsevents o lurasidone; o quetiapine due to an increased risk of toxicity; o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of hepatotoxicity and QT interval prolongation; o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure; o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions; o irinotecan due to an alteration of the metabolism of this medicinal product; o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of these medicinal products; o vardenafil in men older than 75-years due to increased risk of adverse reactions o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions; o fesoterodine and solifenacin in patients with renal impairment; o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone secretion”.
Maltese: o inibituri tal-HMG-CoA reductase metabolizzati minn CYP3A4 (eż simvastatin, atorvastatin u lovastatin) minħabba żieda fir-riskju ta' effett tossiku fuq il-muskoli skeletali, inkluż rabdomijoliżi; o eplerenone minħabba żieda fir-riskju ta' iperkalimja u pressjoni baxxa; o sustanzi li l-konċentrazzjonijiet tagħhom fil-plażma jistgħu jiżdiedu u li jkollhom il-potenzjal ta' titwil tal-QT: methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine; o dabigatran minħabba ż-żieda fir-riskju ta' fsada; o triazolam, midazolam orali u alprazolam minħabba l-potenzjal għal sedazzjoni mtawla jew miżjuda u depressjoni respiratorja; o alkalojdi tal-ergotina (eż. dihydroergotamine, ergometrine (ergonovine), ergotamine u methylergometrine (methylergonovine) minħabba żieda fir-riskju ta' ergotiżmu u reazzjonijiet avversi vażospastiċi serji oħra; o lurasidone; o quetiapine minħabba żieda fir-riskju ta' tossiċità; o telithromycin u clarithromycin f'pazjenti b'indeboliment sever tal-kliewi minħabba żieda fir-riskju ta' epatotossiċità u titwil tal-intervall QT; o felodipine, nisoldipine minħabba żieda fir-riskju ta' edima u insuffiċjenza konġestiva tal-qalb; o colchicine f'pazjenti b'indeboliment tal-kliewi minħabba żieda fir-riskju ta' reazzjonijiet avversi severi; o irinotecan minħabba bidla fil-metaboliżmu ta' dan il-prodott mediċinali; o everolimus, sirolimus (magħruf ukoll bħala rapamycin) minħabba żieda fil-konċentrazzjonijiet filplażma ta' dawn il-prodotti mediċinali; o vardenafil f'irġiel ta' 'l fuq minn 75 sena minħabba ż-żieda fir-riskju ta' reazzjonijiet avversi;